Skip to content

Study · Randomized controlled trial · 2023

4 results

Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.

Liu L, Wang R, Gao J, Yan J, Zhang J, Zhang Z, Liu J, Lin H, Rao S, Yao X, Wu W, Bian H and 4 more

Show all authors

Wang X, Guo S, Gao X, Yan H

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association31 Jul 2023Cited by 4 (Europe PMC)

PMID37524110 (opens in a new tab)PMCIDPMC10645484 (opens in a new tab)DOI10.1055/a-2145-1004 (opens in a new tab)PepBankPUB-37524110
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes and NAFLD, psoas muscle area tended to decrease nonsignificantly during exenatide treatment.

    In plain wordsIn patients with type 2 diabetes and fatty liver, muscle area did not significantly decrease with exenatide compared with baseline.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePsoas muscle area from baseline
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Psoas muscle area decrease
    149.09 mm²
    Exenatide

    Source sentences

    Summary
    After treatment, PMA tended to increase by 13.13 (-215.52, 280.80) mm2 in the insulin glargine group and decrease by 149.09 (322.90-56.39) mm2 in the exenatide group (both p>0.05).
    2 context sentences
    Summary · context
    This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, NAFLD and BMI below 28, adjusted psoas muscle area change favored glargine over exenatide.

    In plain wordsIn patients with diabetes, fatty liver and BMI below 28, glargine increased muscle area more than exenatide after adjustment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePsoas muscle area in BMI below 28 subgroup
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Psoas muscle area difference
    560.64 mm²
    Glargine relative to exenatide

    Source sentences

    Summary
    Subgroup analysis showed a 560.64 (77.88, 1043.40) (mm2) increase of PMA in the insulin group relative to the Exenatide group in patients with BMI2 (p0.031) after adjusting for gender, age, and research center.
    2 context sentences
    Summary · context
    This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment.
  3. 03HumanRandomized controlled trialOther

    In patients with type 2 diabetes and NAFLD, BMI interacted with treatment in the comparison of exenatide and glargine.

    In plain wordsIn patients with type 2 diabetes and fatty liver, BMI modified the treatment effect of exenatide versus glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    MixedBMI-by-treatment interaction
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Interaction analysis showed an interaction between BMI and treatment (p0.009).
    2 context sentences
    Summary · context
    This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment.
  4. 04HumanRandomized controlled trialOther

    In patients with type 2 diabetes and NAFLD, no treatment interaction was observed for exenatide versus glargine in the BMI 28 or more subgroup or across sex and age subgroups.

    In plain wordsIn patients with diabetes and fatty liver, the exenatide versus glargine comparison showed no interaction by BMI of 28 or more, sex, or age.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeTreatment interaction in BMI 28 or more, sex and age subgroups
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    However, no interaction was observed among subgroups with a BMI≥28 kg/m2 or with different genders and ages.
    2 context sentences
    Summary · context
    This study investigated the effects of insulin glargine and exenatide on the muscle mass of patients with newly diagnosed type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a post-hoc analysis of our previously study, a 24-week randomized controlled multicenter clinical trial (ClinicalTrials.gov, NCT02303730). Seventy-six patients were randomly assigned 1:1 to receive insulin glargine or exenatide treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02303730

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Fudan Universityn = 76Mar 2015 to Nov 2017

Diabetes Mellitus, Type 2 · Non-alcoholic Fatty Liver Disease

Trial pageClinicalTrials.govUpdated 28 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.